Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
) o8 r( L; |( b1 s
_0 x& ?/ M* x, w' u
; l E* s% c9 s5 eSub-category:
: h5 D1 f; S! j' r5 ]% a% _Molecular Targets
/ a, i3 [$ [* ^& ^2 v6 w9 I
) V- C) }* T7 A6 o3 ~! W( Z9 S; v7 @" L
Category:3 Z6 G; }/ I# Q3 _% ^
Tumor Biology
7 P& B/ f! R1 W! H3 L- L
3 z2 n3 i& V, g# f1 H, q( U9 y- t4 f
Meeting:+ H; {- e3 m( R
2011 ASCO Annual Meeting 0 J# p# [' E5 `2 F, p
1 P, d3 {" _1 t5 y" o- j- O5 g4 h
& B. R8 c" Z) ~' e& l0 R/ fSession Type and Session Title:" |; w3 i+ N1 ]' r
Poster Discussion Session, Tumor Biology
3 `/ y K7 y# h' O3 K
3 f$ `/ C% N* \* E# J
/ [* v: G' Z: X# ~3 e4 L" r5 FAbstract No:
9 X& K5 c% `- U! m* R8 R10517 # d$ e9 s3 k5 Q3 K9 v {, F
$ y7 _* Y9 _9 u* }
* N# `. P# ] S U/ i
Citation:
$ [. f8 l1 d8 N* HJ Clin Oncol 29: 2011 (suppl; abstr 10517)
{* q0 z k+ b" F) |% @8 p0 e4 l3 {. y. C- i
( I: A6 D G- K9 C! D7 F8 p
Author(s):
; E% h$ X% V9 ~9 x2 rJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 8 W- e; B+ M3 O: N" d6 B. j
0 y! M6 h% z- C6 N+ k
$ ~% F# U3 w. h* {( W$ H
( W- d( q! f3 t' _& |
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 i- G$ y5 D8 q, Z+ c% v7 u3 ?- c. S8 p M- \8 s: x! w
Abstract Disclosures
6 r1 g" H, G" n4 g! w' b
5 g0 ~# n. i/ k c- M! pAbstract:6 m! X: s, \8 W6 T) O
+ G) R+ t; z7 |5 ^
+ L, b4 e" O- h+ ]2 E0 F2 zBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; ], Y3 `! o( E; h6 ?' }
& q$ w) m; o: L$ E* k( y - c3 b9 z' U; T; ?" F% o. K
|